Imvanex (Modified Vaccinia Ankara – Bavarian Nordic Live Virus)

The Modified Vaccinia Ankara (MVA) virus in Imvanex is a highly attenuated strain that expresses orthopoxviral antigens after subcutaneous injection. These antigens stimulate both antibody production and T‑cell responses, creating a robust immune defense against smallpox, monkeypox and related viruses.

The exact dosing regimen for Imvanex is determined by the prescribing healthcare professional. Typically, a series of subcutaneous injections is given according to national immunisation guidelines, but the prescriber sets the schedule based on patient age, risk factors and local recommendations.

Safety data for Imvanex during pregnancy and lactation are limited. The vaccine should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To order Imvanex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Imvanex (MVA) is a non‑replicating, live‑attenuated vaccine, offering a favorable safety profile compared with replication‑competent vaccines such as ACAM2000. While both provide protection against orthopoxviruses, MVA is generally preferred for immunocompromised individuals because it does not cause productive infection.

Imvanex must be stored refrigerated at 2 °C to 8 °C. Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking the solution. Follow cold‑chain procedures during transport to maintain vaccine potency.

Imvanex is given as a subcutaneous injection, typically into the upper arm or thigh. The injection site should be cleaned with an antiseptic, and the vaccine administered using a sterile needle and syringe according to the prescriber’s instructions.

Serious adverse events, although rare, include anaphylaxis, progressive vaccinia in severely immunocompromised patients, encephalitis, myocarditis/pericarditis and severe skin reactions such as Stevens‑Johnson syndrome. Immediate medical attention is required if any of these symptoms occur.

Imvanex is contraindicated in individuals with severe cellular immunodeficiency, those with a known severe allergy to any vaccine component, and pregnant women unless the benefit outweighs the risk. Persons with uncontrolled eczema or atopic dermatitis should be evaluated carefully before vaccination.